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Transcriptional Modulation Using HDACi
Depsipeptide Promotes Immune Cell-Mediated
Tumor Destruction of Murine B16 Melanoma
Takashi Murakami1, Atsuko Sato1,2, Nicole A.L. Chun1, Mayumi Hara1, Yuki Naito1, Yukiko Kobayashi2,3,
Yasuhiko Kano4, Mamitaro Ohtsuki2, Yusuke Furukawa3 and Eiji Kobayashi1
With melanoma, as with many other malignancies, aberrant transcriptional repression is a hallmark of refractory
cancer. To restore gene expression, use of a histone deacetylase inhibitor (HDACi) is expected to be effective.
Our recent DNA micro-array analysis showed that the HDACi depsipeptide (FK228) significantly enhances gp100
antigen expression. Herein, we demonstrate that depsipeptide promotes tumor-specific T-cell-mediated killing
of B16/F10 murine melanoma cells. First, by a quantitative assay of caspase-3/7 activity, a sublethal dose of
depsipeptide was determined (ED50: 5 nM), in which p21Waf1/Cip1 and Fas were sufficiently evoked concomitantly
with histone H3 acetylation. Second, the sublethal dose of depsipeptide treatment with either a recombinant
Fas ligand or tumor-specific T cells synergistically enhanced apoptotic cell death in B16/F10 cells in vitro.
Furthermore, we found that depsipeptide increased levels of perforin in T cells. Finally, in vivo metastatic growth
of B16/F10 in the lung was significantly inhibited by a combination of depsipeptide treatment and immune cell
adoptive transfer from immunized mice using irradiated B16 cells and gp100-specific (Pmel-1) TCR transgenic
mice (Po0.05, vs cell transfer alone). Consequently, employment of a transcriptional modulation strategy using
HDACis might prove to be a useful pretreatment for human melanoma immunotherapy.
Journal of Investigative Dermatology (2008) 128, 1506–1516; doi:10.1038/sj.jid.5701216; published online 10 January 2008
INTRODUCTION
Great efforts have been made in the field of tumor immuno-
logy, and attempts to enhance cellular immune responses
have used various cancer antigens and immunizing vectors
(Rosenberg, 2004; Gattinoni et al., 2006). Although these
strategies allow for the generation of immune T cells that
recognize antigenic peptides present on tumor cells, the
regression of growing tumors in patients treated with active
immunization has been sporadic and rare (Rosenberg et al.,
2004). In fact, a variety of factors that limit tumor regression
despite the in vivo generation of antitumor T cells have been
reported (Rosenberg and Dudley, 2004), and it is therefore
necessary to overcome many tumor and lymphocyte factors
that cause the tumor-escape mechanisms. Targeting key
survival pathways in tumor cells, particularly those that allow
cancer cells to prevent host immune attacks, is an attractive
approach when aiming for an increase in the effectiveness of
cancer immunotherapy.
There are emerging data suggesting that aberrant trans-
criptional repression of genes to control cell growth and
differentiation is a hallmark of malignancy (Herman and
Baylin, 2003). With melanoma, as with many other cancers,
alteration of histone deacetylases (HDACs) underlies the
transcriptional repression (Klisovic et al., 2003; Kobayashi
et al., 2006). Thus, blockade of HDACs might restore global
gene expression in cancer cells, making them sensitive to
cell cycle arrest, differentiation, and apoptotic cell death
(Johnstone and Licht, 2003; Minucci and Pelicci, 2006). The
action mode of histone deacetylase inhibitors (HDACis), as
the transcriptional modulator, differs from that of other anti-
cancer agents (Marks et al., 2001), and HDACis are expected
to be effective for many cancer types that resist conventional
chemotherapy (Marks et al., 2001; Minucci and Pelicci,
2006). Indeed, HDACis have shown cytotoxicity in a variety
of human and rodent cancer cells in vitro and in vivo
(Hoshikawa et al., 1994), some of which are being tested in
clinical studies (Minucci and Pelicci, 2006).
Depsipeptide (also referred to as FK228 and FR901228)
may be considered a promising HDACi for human mela-
noma. It was originally isolated from Chromobacterium
violaceum (no. 968) as a compound that reversed the
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malignant phenotype of H-ras-transformed fibroblasts by
blocking the p21ras-mediated signal transduction pathway
(Ueda et al., 1994a, b). Depsipeptide suppressed cell proli-
feration and induced apoptosis in human uveal melanoma
cell lines at relatively high doses (Klisovic et al., 2003) and
produced substantial therapeutic effects on various malig-
nancies (Minucci and Pelicci, 2006). In our previous study to
determine the molecular basis of its cytotoxic effect,
depsipeptide suppressed the Ras-mitogen-activated protein
kinase signaling pathway through Rap1 upregulation, leading
to apoptosis in human melanoma cells (Kobayashi et al.,
2006). Herein, we show that depsipeptide sensitized poorly
immunogenic murine B16 melanoma cells to the Fas ligand
and that a limited dose of depsipeptide suppressed in vivo
growth of B16/F10 in combination with adoptive immune
cell transfer therapy. Consequently, a transcriptional mod-
ulation strategy using HDACis might prove to be a useful
adjunct in human immunotherapy strategies against cancer.
RESULTS
Depsipeptide enhances expression of gp100/pmel17 melanoma
antigen in melanoma cell lines
Our recent DNA micro-array study revealed that the HDACi
depsipeptide markedly enhanced mRNA expression of gp100/
pmel17 melanoma antigen in MM-LH human melanoma cells
(15-fold increase) (Kobayashi et al., 2006). Thus, we initially
hypothesized that gp100/pmel17 would be a potential target
of depsipeptide in human melanoma cells. The expression of
gp100/pmel17 in human melanoma cell lines was examined
by reverse transcription-PCR (RT-PCR) (Figure 1a). All mela-
noma cell lines examined showed strong enhancement of
gp100/pmel17 mRNA expression after exposure to depsipep-
tide (10nM) for 16hours, whereas normal healthy melano-
cytes were not affected by the same dose of depsipeptide. The
expression of gp100/pmel17 by depsipeptide was moderately
enhanced in murine B16/F10 melanoma cells.
To characterize the effects of depsipeptide in a murine
model of melanoma, we examined the ability of depsipeptide
to induce histone acetylation in B16/F10 cells (Figure 1b).
Basal acetylation of histone H3 (lysine residue 9) was detec-
ted, and subsequent experiments revealed that the acetylation
level of histone H3 (lysine residues 9 and 18) increased
significantly after a 24 hour exposure to 1–10 nM depsipep-
tide. Furthermore, major histocompatibility complex (MHC)
class I (H2-Db) and Fas (CD95) death receptor expression
were enhanced in B16/F10 cells exposed to depsipeptide
(Figure 1c). In human melanoma cell lines, to depsipeptide
resulted in moderately enhanced MHC class I expression but
not Fas expression (Figure S1). Thus, a 1–10 nM depsipeptide
dose could sufficiently modulate murine B16/F10 melanoma
cells within 16 hours in vitro, suggesting that a limited dose of
depsipeptide may be effective for recognition and sensitiza-
tion of immune cell-mediated tumor destruction in mice.
A limited dose of depsipeptide moderately induces apoptosis
and cell cycle arrest in murine B16 melanoma cells
We have shown previously that depsipeptide induces apop-
totic cell death in human melanoma cell lines (Kobayashi
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Figure 1. Depsipeptide enhances expression of gp100/pmel17 melanoma antigen. (a) RT-PCR analysis of gp100/pmel17 transcript. Total RNA was
extracted from each melanoma cell line after exposure to depsipeptide (10 nM) for 16 hours. PCR was performed with primers as described in Materials and
Methods. GAPDH, glyceraldehyde-3-phosphate dehydrogenase (as an internal control); NHEM, normal healthy melanocytes; MC (RPM-MC), BP (MM-BP),
LH (MM-LH), and RU (MM-RU) are human melanoma cell lines. One of three independent experiments with similar results is shown. (b) Effect of depsipeptide
on histone deacetylation in B16/F10 cells. B16/F10 cells (2 106) were exposed to depsipeptide at the indicated concentration for 16 hours. Cells were
lysed and analyzed for anti-acetyl-histone H3 (Lys 9), anti-acetyl-histone H3 (Lys 18) and anti-histone H3 by western blotting. (c) Expression of MHC class I
(H-2Db) and Fas (CD95) in B16/F10 cells following exposure to depsipeptide. B16/F10 cells were exposed to depsipeptide at the indicated concentration
for 16 hours and stained with PE-conjugated anti-H-2Db or Fas mAb. The control was treated with PBS. One of 2–3 independent experiments with similar
results is shown.
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Figure 2. Depsipeptide activates caspase-3/7 and accompanies cell cycle arrest in B16/F10 cells. (a) Luc-B16/F10 cells (1 105) were plated onto
48-well plates at the indicated number and exposed to depsipeptide at the indicated concentration for 16 hours. Luciferase activity (photon counts) was
then evaluated in the presence of D-luciferin. (b) Caspase-3/7 activity was quantified for 16 hours following treatment at the indicated concentration of
depsipeptide in B16/F10 cells (2104). The Caspase-Glo 3/7 Assay system (Promega) was used according to the manufacturer’s instructions. The background
luminescence associated with the cell culture and assay reagent (blank reaction) was subtracted from experimental values. (c) Western blot analysis of
p21Waf1/Cip1 and phospho-RB (Ser780) 16 hours following treatment at the indicated concentration of depsipeptide. b-actin was used as an internal control.
One of two independent experiments with similar results is shown.
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Figure 3. A sublethal dose of depsipeptide with Fas engagement synergistically promotes apoptotic cell death in B16/F10 cells in vitro. (a) B16/F10 cells
(1106) were treated with depsipeptide (5 nM) and recombinant FLAG-tagged FasL (10 ngml1) and multimerized with anti-FLAG M2 antibodies
(1mgml1) for 16 hours. Cells were then collected and stained with annexin-V-FITC. One of two independent experiments with similar results is shown.
(b) Caspase-3/7 activity after exposure to depsipeptide with Fas engagement. The Caspase-Glo 3/7 Assay system (Promega) was used as described
above. *Po0.05; **Po0.001 (Student’s t-test).
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et al., 2006). As photon emission from luciferase-expressing
luc-B16/F10 cells was highly correlated with viable cell
number (Sato et al., 2006), we examined a sublethal dose of
depsipeptide on murine B16/F10 melanoma cells (Figure 2a).
Results revealed that depsipeptide decreased tumor-derived
photons in a dose-dependent manner. Furthermore, caspase-
3/7 activity in unmanipulated B16/F10 cells also increased
linearly after a 24 hour exposure to 1–10 nM depsipeptide
(Figure 2b), with the median dose of depsipeptide (ED50)
being 5.34 nM. The increase in caspase-3/7 activity was
accompanied by a dose-dependent increase in the expression
of the cell cycle regulator p21Waf/Cip1, and the Rb protein
was dephosphorylated at the critical residue Ser780 for the
cell cycle (Figure 2c). Thus, a sublethal dose of depsipeptide
could moderately induce apoptosis and cell cycle arrest in
murine B16/F10 melanoma cells.
Depsipeptide with Fas death receptor engagement
synergistically promotes apoptosis in B16/F10 melanoma cells
In mechanisms associated with lymphocyte-mediated tumor
killing, the Fas and Fas ligand (FasL) system is a well-known
major pathway in mice (Kagi et al., 1994; Caldwell et al.,
2003; Lee et al., 2006). We therefore examined whether
a sublethal dose of depsipeptide (ED50: 5 nM) promoted FasL-
triggered apoptosis. B16/F10 cells were exposed to depsipep-
tide in the presence or absence of multimerized FasL, which
was measured by annexin-V staining (Figure 3a). In the
presence of depsipeptide, B16/F10 cells readily induced
apoptotic cell death after Fas–FasL crosslinking, whereas B16/
F10 cells were resistant to apoptosis with Fas crosslinking
alone. Caspase-3/7 activity was also synergistically enhanced
in the presence of depsipeptide and FasL (Figure 3b).
Pan-caspase inhibition in tumor cells treated with Z-VAD-
fmk almost totally cancelled the enhanced cytotoxic effect.
We next investigated whether a sublethal dose of
depsipeptide promoted cytotoxicity induced by melanoma
antigen-specific cytotoxic T lymphocytes (CTLs). To generate
B16/F10-specific CTLs, C57BL/6 mice were immunized twice
by subcutaneous (s.c.) injection of irradiated IL-12/IL-18-
transduced B16/F10 cells (Sato et al., 2006). Spleen cells
from immunized mice showed enhanced production of
IFN-g (Figure 4a) and moderate killing activity with respect
to B16/F10 cells (data not shown). Strikingly, the spleen
cells demonstrated efficient killing of luc-B16/F10 cells in
the presence of depsipeptide (Figure 4b). Furthermore, we
investigated whether depsipeptide-exposed luc-B16/F10 cells
could be killed by CD8þ T cells from a transgenic mouse
(Pmel-1), which expressed Va2Vb13 TCR from H-2Db-
restricted murine gp100-specific clone no. 9 T cells (Over-
wijk et al., 2003). As shown in Figure 5a, Pmel-1 T cells were
also capable of efficiently killing depsipeptide-exposed luc-
B16/F10 cells. Depsipeptide at 5 nM moderately enhanced
the surface expression of FasL in antigen-activated Pmel-1 T
cells (Figure 5b). Furthermore, to examine whether pmel-1
CTL killing of luc-B16/F10 was primarily mediated by
Fas–FasL-dependent pathway, we assessed the effect of anti-
FasL neutralizing antibodies on the luc-B16/F10 killing. Anti-
FasL mAb (20 mgml1) inhibited Pmel-mediated killing of
depsipeptide-treated luc-B16/F10 cells at lower effector-to-
target ratios (Figure 5c). This anti-FasL mAb could not
sufficiently block the Pmel-mediated killing even at a high
concentration (50 mgml1, Figure 5d). Thus, in regard to the
mechanism underlying the synergistic effect of depsipeptide
and CTL cells, the CTL-mediated killing of B16 cells was not
completely dependent on Fas–FasL interactions.
Depsipeptide increases perforin in activated CD8þ
T lymphocytes
We further addressed the effects of depsipeptide on acti-
vated CD8þ T cells in vitro. The trypan blue exclusion test
showed that depsipeptide at 5 nM had little effect on viability
of antigen-activated Pmel-1 CTLs within 24 hours (data
not shown). An alternative hypothesis is that depsipeptide
may enhance immune effector cell function to produce the
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Figure 4. Melanoma-specific CTLs with depsipeptide can synergistically
kill B16/F10 cells in vitro. (a) IFN-g levels from splenocytes were assayed
by ELISA. Splenocytes (2105) were isolated after the second immunization
using irradiated IL-12/IL-18 cDNA-transduced B16/F10 cells and were
co-cultured for 24 hours with 1105 target cells (irradiated with 80Gy).
The IFN-g concentration of the supernatants was measured using a mouse
IFN-g immunoassay kit (R&D Systems, Minneapolis, MN) according to
the manufacturer’s instructions. EL-4 thymoma cells were used for control
H-2b tumor cells for a B16-specific IFN-g increase. Error bar, SD (n¼3).
A representative result of three independent experiments with similar
results is shown. (b) Cytotoxic assay against depsipeptide-exposed luc-B16/
F10 cells. C57BL/6 mice were immunized by s.c. injection of irradiated
IL-12/IL-18 cDNA-transduced B16/F10 cells. Spleen cells were isolated
and used as effectors at the indicated effector-to-target (E:T) ratios. Photons
represent cell viability from luc-B16/F10 cells 10 hours following incubation
with effector lymphocytes. Data are shown as the average of triplicate assays.
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antitumor response. Pmel-1 T cells were exposed to depsi-
peptide in the presence or absence of antigen stimulation,
and expression of perforin was analyzed using flow cyto-
metry (Figure 6a). Although perforin expression levels did not
alter in unstimulated Pmel-1 T cells following exposure to
5 nM depsipeptide for 24 hours, cells that express perforin
increased in antigen-stimulated Pmel-1 T cells. To address
whether perforin mRNA expression in Pmel-1 T cells could
be altered by exposure to depsipeptide, RT-PCR analysis was
performed (Figure 6b). The results demonstrated that levels of
perforin mRNA did not alter following exposure to multiple
concentrations of depsipeptide. These results, therefore,
suggest that perforin expression by exposure to depsipeptide
is regulated at post-transcriptional levels. An increase of
perforin was also observed in healthy human peripheral
CD8þ T cells stimulated with phytohemagglutinin-P (PHA-P)
for 24 hours (Figure 6c) and an accumulation of perforin was
observed in a small number of these T cells (Figure S2). These
results suggest that depsipeptide potentially increases the
number of cells that express perforin in murine-activated
CD8þ T cells and that it enhances intracellular perforin
accumulation in human T cells. These results may support the
notion of an antitumor response in the host.
Inhibition of tumor growth of B16/F10 by a combination of
depsipeptide with immune cell adoptive transfer therapy
To examine whether a sublethal dose of depsipeptide
sensitizes B16/F10 cells in vivo for adoptive immunotherapy,
growth retardation of established B16/F10 s.c. tumor in
C57BL/6 mice (see Materials and Methods) was monitored
after intraperitoneal injection of depsipeptide and subsequent
adoptive transfer of Pmel-1 CTLs (Figure 7a). Depsipeptide
intraperitoneal administration was performed for 3 days at the
indicated doses. Established B16/F10 s.c. tumor growth was
retarded with 2mgkg1 of depsipeptide at 7 days post-Pmel-1
CTL transfer. The acetylation level of histone H3 (lysine 18)
also increased following depsipeptide treatment at target
tumor sites (Figure 7b). Notably, this modulation was
preferentially observed in the margin and perivascular area
of the formed tumor (Figure S3a). A moderate induction
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Figure 5. Gp100-specific CTLs with depsipeptide can synergistically kill B16/F10 cells in vitro. (a) Killing of depsipeptide-exposed luc-B16/F10 cells by
gp100-specific CD8þ T cells from a transgenic mouse (Pmel-1). Pmel-1 cells were used as effectors at the indicated effector-to-target (E:T) ratios. One of
three independent experiments with similar results is shown. (b) Expression of FasL (CD178) in Pmel-1 T cells following exposure to depsipeptide.
Antigen-stimulated Pmel-1 T cells were exposed to depsipeptide at 5 nM for 16 hours and stained with PE-conjugated anti-FasL mAb. (c) Effect of neutralizing
anti-FasL mAb on Pmel-1 CTL-mediated B16/F10 killing. Depsipeptide (5 nM)-exposed luc-B16/F10 cells were co-incubated with Pmel-1 CTLs for
16 hours in the presence of ant-FasL mAb (20mgml1) or isotype-matched control Ab (20mgml1). (d) Depsipeptide (5 nM)-exposed luc-B16/F10 cells
were incubated with Pmel-1 CTLs at a 10:1 (E:T) ratio for 16 hours with various concentrations of ant-FasL mAb. One of two independent experiments
with similar results is shown.
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*Po0.05 (Kruskal–Wallis test; at days 16 and 19 after tumor implantation). One of three independent experiments with similar results is shown.
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of gp100/pmel17 was also observed by RT-PCR assay
(Figure S3b). Thus, these data demonstrate that a limited dose
of depsipeptide (2mgkg1) sufficiently sensitized
B16/F10 cells in vivo for adoptive immunotherapy. Regarding
the perforin modulation, we could not determine whether
perforin induction occurred in vivo by FACS analysis.
We further investigated whether s.c. tumor growth of
B16/F10 cells could be inhibited by the adoptive transfer of
Pmel-1 CTLs in combination with depsipeptide (Figure 7c).
After waiting about a week for tumor growth, 2mg kg1 of
depsipeptide was administered via the intra-peritoneal route,
followed by the adoptive transfer of Pmel-1 CTLs. In contrast
to either CTL transfer alone or depsipeptide pretreatment
alone, this combinatorial treatment strikingly suppressed
B16/F10 tumor growth. Moreover, we examined whether
the above depsipeptide pretreatment and a similar CTL
transfer could suppress metastatic tumor growth (Figure 8).
Luc-B16/F10 cells were intravenously injected into the tail
vain of C57BL/6 mice, and pulmonary metastasis of luc-B16/
F10 cells was monitored through luciferase-based lumines-
cent imaging. After waiting about a week for tumor growth,
animals were treated with 2mg kg1 of depsipeptide for
3 days, followed by the adoptive transfer of CTLs, which were
generated by immunization using irradiated IL-12/IL-18-
transduced B16/F10 cells. This combinatorial treatment
significantly suppressed tumor-derived photons in pulmonary
metastases 21 days following tumor injection. Similar sup-
pression of pulmonary metastases was obtained by adoptive
transfer of Pmel-1-derived CTLs (data not shown). Thus, these
results demonstrate that sensitization using a limited dose
of depsipeptide increases the efficacy of adoptive immuno-
therapy for established tumors.
DISCUSSION
Cellular unresponsiveness of solid tumor through aberrant
transcriptional regulation represents a critical barrier that
limits the therapeutic potential of adoptively transferred
autologous CTLs in patients with cancer. Herein, we have
demonstrated that tumor sensitization with depsipeptide
is effective for adoptive immunotherapy against murine
B16/F10 melanoma. The remarkable features presented in
this study include the following: (1) depsipeptide upregulated
gp100/pmel17 melanoma antigen; (2) a limited dose of
depsipeptide was able to sufficiently sensitize B16/F10 cells
for Fas-mediated apoptosis; (3) depsipeptide increased the
perforin-expressing CTLs in post-transcriptional levels; and
(4) adoptive cell transfer in combination with depsipeptide
led to effective tumor growth suppression.
Emerging evidence suggests that there are a variety of
factors that limit tumor regression in the host–tumor interac-
tion. For example, cancer progression often takes place
despite the presence of circulating cancer-specific CTLs. Even
with patients in whom large numbers of highly activated
tumor-specific CTLs have been infused, clinical improvement
has been difficult to achieve (Dudley et al., 2001; Rosenberg,
2004). For example, recent evidence concerning host factors
suggests that regulatory elements of the immune responses,
including CD4þCD25þ regulatory T cells (Tregs), inhibit
the ability of CTLs to produce effective antitumor responses
(Antony and Restifo, 2005; Dannull et al., 2005). In regard
to tumor-escape factors, many aggressive tumors do not
express the tumor antigen or MHC (HLA) antigen (Ferrone
and Marincola, 1995; Cabrera et al., 2003). Moreover, many
cancer types lack sufficient apoptotic cell death pathways
through the aberrant transcription (Johnstone et al., 2002;
Maecker et al., 2002). It is theoretically essential to overcome
these tumor-escape factors for efficient cancer immunother-
apy, and perhaps to manipulate the tumor, as well as the host,
before adoptive immune cell transfer.
HDACs are considered among the most promising targets
in drug development for cancer, and some HDACi, including
depsipeptide (FK228), are currently being tested in phase I
and II clinical trials (Minucci and Pelicci, 2006). HDACi
is capable of inducing varying degrees of growth arrest,
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Figure 8. Depsipeptide pretreatment and B16-specific CTLs transfer suppress metastatic tumor growth of B16/F10 cells. (a) Representative luciferase images
of luc-B16/F10 metastatic lung tumor at day 15 after combinatorial therapy of depsipeptide (2mg kg1) and immune cell adoptive transfer from immunized
mice using irradiated IL-12/IL-18-transduced B16/F10 cells. (b) Photon counting of luc-B16/F10-pulmonary metastasis at day 21 (n¼6–7). #Po0.01
(Kruskal–Wallis test). One of three independent experiments with similar results is shown.
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differentiation, or apoptosis of cancer cells (Johnstone et al.,
2002; Minucci and Pelicci, 2006). In addition, normal fibro-
blasts and melanocytes are almost always considerably more
resistant than tumor cells to depsipeptide (Kobayashi et al.,
2006; Minucci and Pelicci, 2006), suggesting this effect may
be specific to malignant cells. We demonstrated the potential
upregulation of MHC class I molecules by depsipeptide
treatment. As the MHC class I molecule is released from the
endoplasmic reticulum only after the peptide has bound and
is allowed to reach the cell surface (Williams et al., 2002),
this upregulation could provide substantial benefits for the
immunological recognition. However, there are abnormal-
ities in the expression and/or function of various components
of the MHC class I antigen-processing pathway in human
malignant cells (Seliger et al., 2000; Chang and Ferrone,
2007), and it remains to be elucidated whether HDACi affects
various components of the protein-processing machinery.
Although the clinical use of depsipeptide when adminis-
tered alone showed partial and complete responses in
patients with hematological malignancy (Piekarz et al.
2001, 2004; Byrd et al., 2005), only a partially objective
response was observed in solid cancer patients (Sandor et al.,
2002; Stadler et al., 2006), suggesting that depsipeptide
alone appears far from beneficial in the treatment of cancer
patients. However, moving the focus onto the modulation
of tumor factors and targeting HDACs could provide great
benefits, particularly for selective immunotherapy against
cancer. Intriguingly, HDACi could activate components of
death receptor pathways, including FasL and tumor necrosis
factor-related apoptosis-inducing ligand (TRAIL) (Nakata
et al., 2004; Singh et al., 2005; Earel et al., 2006). In fact,
B16/F10 cells are less immunogenic and highly resistant to
a variety of apoptotic stimuli if they are not manipulated
(Avent et al., 1979; Tsai et al., 1997; Kalechman et al., 1998).
Nonetheless, exposure of B16 cells to a limited dose of
depsipeptide induced cell surface expression of Fas and MHC
class I, and the enforced Fas-engagement synergistically
increased caspase-3/7 activity of B16/F10 cells in the pre-
sence of depsipeptide (Figure 3). Furthermore, these changes
successfully provided CTLs with an enhanced ability to
recognize and destroy target tumor cells (Figures 4 and 5).
Indeed, it has been demonstrated that HDACi synergizes
with exogenously added TRAIL to induce apoptosis of various
human solid tumor cell lines in vitro (Inoue et al., 2004;
Nakata et al., 2004; Singh et al., 2005; Lundqvist et al.,
2006). While the TRAIL system seems to be relatively major
in the effect of HDACi on the human death receptor pathway,
it has been suggested that the effect of HDACi on the death
receptor pathway may not be universal (Minucci and Pelicci,
2006). We could not obtain a synergistic effect of depsipep-
tide with FasL in Fas-negative human MM-LH cells, and
mouse Pmel-1 T cells did not express TRAIL on the cell
surface (unpublished data). The Fas–FasL system is well
known as the major pathway of CTL-mediated tumor destruc-
tion in murine models (Kagi et al., 1994; Caldwell et al.,
2003; Lee et al., 2006), and therefore some differences
between species should be considered for the major death
receptor pathway. However, current animal studies have
demonstrated that the augmented tumoricidal effects of
tumor-specific CTLs induced as a consequence of depsipep-
tide sensitization resulted in melanoma cells that produced
CTL-mediated cytotoxicity in vivo. A limited administration
of depsipeptide also sufficiently modulated the acetylation
level of histone H3 at the tumor site (Figure 7b). These
findings may provide the rationale for protocols that pretreat
cancer patients with depsipeptide to potentiate adoptive
immune therapy.
Emerging experimental data indicate that lymphodeple-
tion using cyclophosphamide before adoptive transfer of
tumor-specific T lymphocytes plays a key role in enhancing
treatment efficacy by eliminating regulatory T cells and
competing elements of the immune system (Ghiringhelli
et al., 2004; Lutsiak et al., 2005). Furthermore, pretreatment
with cyclophosphamide contributes to the elimination of
immunosuppressive cells such as CD4þCD25þ Treg in
patients with cancer and the depletion of endogenous cells
that compete for the activation of cytokines (known as the
‘‘cytokine sink’’) to maximize the exposure of homeostatic
cytokines to the transferred CTLs (Gattinoni et al., 2006).
In addition to this pretreatment, depsipeptide may safely be
added to reduce barrier tumor factors limiting the therapeutic
potential of adoptively transferred CTLs. We further demons-
trated that depsipeptide increased the level of perforin in
activated T cells to varying degrees: the number of perforin-
expressing CTLs increased in mice, whereas an accumulation
of perforin was observed in humans. Perforin release by
T cells in conjunction with granzymes induces an apoptotic
cascade in target cells (Kagi et al., 1994). In fact, Palmer et al.
(2004) showed that there was a B16 cell-dependent release of
perforin after adoptive cell transfer of pmel-1 T cells, in which
caspase-3 activation was also shown at the tumor site as
a consequence of the downstream activation of perforin.
Therefore, the residual depsipeptide in the plasma of pre-
treated hosts could be expected to release large amounts of
toxic granules to the target tumor at the sites and, in combi-
nation with cyclophosphamide, the use of depsipeptide may
be considered for host and tumor modulation before adoptive
tumor-specific CTL transfer.
The therapeutic options for patients with metastatic
disease remain limited, and the majority of these patients
will develop a local or systemic recurrence. A variety of
human cancers such as melanoma and breast, colon, and
prostate cancers aberrantly express the chemokine receptor
CXCR4 (Balkwill, 2004; Kakinuma and Hwang, 2006;
Zlotnik, 2006), and its activation through prosurvival path-
ways such as Akt has been implicated as a mechanism by
which cancer cells evade host immunity (Murakami et al.,
2003) and increase their metastatic properties (Kakinuma
and Hwang, 2006). Recently, Lee et al. (2006) reported that
sensitization of B16 cells with a CXCR4 antagonistic peptide
increases the efficacy of immunotherapy for pulmonary
metastases, suggesting that the inhibition of tumor factor is
an effective strategy for melanoma immunotherapy. Herein,
we also provide compelling in vitro and in vivo data
suggesting that sensitization of less immunogenic B16 cells
with depsipeptide facilitates the efficacy of immunotherapy
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for established pulmonary metastases. Further investigations
based on the findings of this study, especially those
incorporating in vivo techniques, should improve the design
of optimized clinical protocols.
MATERIALS AND METHODS
Animals, cells, and reagents
Male C57BL/6 J mice (8–12 weeks old) were purchased from Charles
River Japan Inc. (Tsukuba, Japan). Pmel-1 TCR pmel-1þ /Thy1.1þ
transgenic mice (Overwijk et al., 2003) were obtained from The
Jackson Laboratory (Bar Harbor, ME). All experiments in this study
were approved by the animal ethics review board of Jichi Medical
University and performed in accordance with the Jichi Medical
University Guide for Laboratory Animals, following the principles of
laboratory animal care formulated by the National Society for
Medical Research.
Human melanoma cell lines RPM-MC, MM-LH, MM-BP, and
MM-RU were kindly provided by Dr H. Randolph Byers (Boston
University Medical School) and maintained in minimal essential
medium supplemented with 10% heat-inactivated fetal calf serum
(FCS) (Byers et al., 1991). Murine B16/F10 melanoma cells (Fidler,
1973) and EL-4 thymoma cells (Ralph, 1973) were grown in DMEM
(GIBCO, Gaithersburg, MD) with 10% FCS and supplements (Sato
et al., 2006). Luciferase-expressing B16/F10 (luc-B16/F10) cells were
generated previously (Sato et al., 2006) and maintained in DMEM
with 10% FCS and supplements, including puromycin (10 mgml1;
Sigma-Aldrich, St Louis, MO). Normal human epidermal melano-
cytes were purchased from Kurabo Biomedicals (Osaka, Japan) and
maintained in Medium 154S with supplement (Kobayashi et al.,
2006). The cultures were kept in a humidified atmosphere contain-
ing 5% CO2 and 95% air at 371C.
Anti-acetyl-histone H3 (Lys 9), anti-acetyl-histone H3 (Lys 18),
anti-histone H3, and anti-phospho-Rb (Ser 780) antibodies were
purchased from Cell Signaling Technology (Beverly, MA). Anti-
mouse p21Waf1/Cip1 (BD Pharmingen, San Diego, CA), anti-human
perforin (clone dG9; BD Pharmingen), and anti-actin (sc-1616, Santa
Cruz Biotechnology Inc., Santa Cruz, CA) antibodies were used
for western blotting. Flow cytometric analysis involved the use of
phycoerythrin (PE)-conjugated anti-mouse H-2Db mAb, PE-conju-
gated anti-mouse Fas (CD95) mAb, PE-conjugated anti-mouse FasL
(CD178) mAb, and isotype-matched IgG controls, all of which were
purchased from BD Pharmingen. FITC-conjugated anti-mouse
perforin mAb (clone: eBioOMAK-D) was purchased from
eBioscience (San Diego, CA). Anti-mouse FasL mAb (clone MFL3;
BD Pharmingen) was used for the FasL neutralization.
The expression plasmids for mouse IL-12 and IL-18, pCAGGS-IL-12
and pcDNA-mproIL-18-mICE respectively, have been described
previously (Ajiki et al., 2003). Depsipeptide (FK228) was obtained
from Gloucester Pharmaceuticals (Cambridge, MA).
Reverse transcription-PCR
Total RNA was extracted from cells using Isogen (Nippon Gene,
Toyama, Japan). Two micrograms of total RNA was used for
first-strand synthesis using SuperScript III reverse transcriptase
(Invitrogen, Carlsbad, CA). PCR was then performed using ExTaq
polymerase (Takara, Ohtsu, Japan). The following primers were used
for gp100/pmel-17 and perforin expression analysis: human gp100/
pmel-17 sense, 50-CCTCCTTCTCTATTGCCTTG-30; human gp100/
pmel-17 anti-sense, 50-TGTAGGAGAGGTGAGCTTCA-30; mouse
gp100 sense, 50-GGCCAACAACACCATCATCA-30; mouse gp100
anti-sense, 50-GGGCAAAGATGAGAGGATGA-30; mouse perforin
sense, 50-ACAATAACAATCCCCGGTGG-30; mouse perforin anti-
sense, 50-TGGGATTAAAGGCGTGTGCT-30; glyceraldehyde-3-phos-
phate dehydrogenase sense, 50-GTATCGTGGAAGGACTCATG-30;
and glyceraldehyde-3-phosphate dehydrogenase anti-sense, 50-AGT
GGGTGTCGCGCTGTTGAAG-30. PCR conditions for each set of
primers included an initial treatment at 951C for 2minutes, followed
by 30 cycles consisting of denaturation at 951C for 15 seconds,
annealing at 571C for 30 seconds, and then extension at 721C for
2minutes. PCR products were analyzed using a 1% agarose gel.
Transfection and ELISA
B16/F10 cells (1 106) were transfected with pCAGGS-IL-12 (5mg)
and pcDNA-mproIL-18-mICE (5 mg) using Lipofectamine 2000
(Invitrogen). Immunization experiments involved irradiating IL-12/
IL-18-transfected B16 cells with 80Gy 36hours after transfection.
Irradiated cells (1–2 105) were then injected twice into the
subcutaneous space of C57BL/6 mice during the remaining weeks.
To analyze IFN-g production, splenocytes (1–2 105) that were
isolated from immunized mice were co-cultured for 24 hours
with 1 105 irradiated target cells, and the IFN-g concentration of
supernatants was then measured using a mouse IFN-g immunoassay
kit. All samples were assayed in triplicate.
Apoptosis and cytotoxic assay
To detect caspase-3/7 activity, B16/F10 cells (2 104 per well of a
96-well plate) were plated, and the Caspase-Glo 3/7 Assay system
(Promega, Madison, WI) was used for analysis in accordance with
the manufacturer’s instructions 16 hours after the addition of
depsipeptide. The background luminescence associated with the
cell culture and assay reagent (blank reaction) was subtracted from
experimental values. Means of triplicates were used to represent
caspase-3/7 activity for the given cells. Each experiment was
performed three times with similar results.
For enhancement of Fas-mediated apoptosis, B16/F10 cells were
exposed to 10 ngml1 recombinant human FLAG-tagged FasL
(Apotech, San Diego, CA) in combination with 1mgml1 anti-FLAG
M2 mAb (Sigma, St Louis, MO) for 16 hours with 5 nM depsipeptide
at 371C in the presence of 0.5% FCS, as described previously
(Murakami et al., 2003). After exposure of B16/F10 cells to
apoptosis-enhancing conditions for 16 hours, attached (and de-
tached) cells were collected from tissue culture plates for annexin-V
staining according to the manufacturer’s instructions (MEBCYTO
Apoptosis Kit; MBL, Nagoya, Japan). Analysis of caspase-3/7 activity
involved the assessment of 2 104 cells using the Caspase-Glo 3/7
Assay system (Promega).
Western blotting and flow cytometry
For western blotting, cells were lysed by sonication in radio-
immuno-protein assay (RIPA) buffer (Sato et al., 2006) and then
centrifuged for 10minutes at 41C. Each cell extract (10 mg of
protein) was assayed using appropriate antibodies and protein
G-conjugated horseradish peroxidase (Amersham Pharmacia
Biotech, Buckinghamshire, UK).
For the flow cytometric analysis, cells (1 106) were washed
with phosphate buffered saline (PBS) and incubated with mAb for
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30minutes at 41C. Following washing with 0.1% FCS-PBS, cells
were analyzed using FACS Calibur (Becton Dickinson, Mountain
View, CA) and FlowJo analysis software (Tree Star, San Carlos, CA).
Subcutaneous and intravenous tumor inoculation
Cells in an exponential growth phase were harvested by trypsiniza-
tion and washed twice in PBS before injection. For the s.c.
injections, cells (1 106) were injected into the abdominal
subcutaneous space of C57BL/6 mice. Tumor growth at the skin
was monitored by measurement of the two maximum perpendicular
tumor diameters. For the intravenous injections to the lungs,
luc-B16/F10 cells (5 104 in 0.2ml PBS) were injected into the tail
vein of C57BL/6 mice. Each experiment was performed 2–4 times
with similar results.
In vivo bioluminescence imaging
In vivo tumor progression was examined using the noninvasive
bioimaging system IVIS (Xenogen, Alameda, CA). Tumor-implanted
mice were anesthetized with a mixture of ketamine and xylazine,
and D-luciferin (potassium salt; Biosynth, Postfach, Switzerland) was
injected into the peritoneal cavity at 2mg per animal, which was
followed immediately by the measurement of luciferase activity. The
imaging system consisted of a cooled, back-thinned charge-coupled
device camera to capture both a visible light photograph of the
animal taken with light-emitting diodes and a luminescent image.
After acquiring photographic images of each mouse, luminescent
images were acquired with a 1–15minutes exposure time (Ohsawa
et al., 2006; Sato et al., 2006). Images were obtained with a 25 cm
field of view, a binning (resolution) factor of 8, 1/f stop, and an open
filter. The resulting gray scale photographic and pseudo-color
luminescent images were automatically superimposed by software
to facilitate the identification of any optical signal and the location
on the mouse. Optical images were displayed and analyzed using
Igor (WaveMetrics, Lake Oswego, OR) and IVIS Living Image
(Xenogen) software packages. The signal from tumors was quantified
as photons flux in units of photons per second per cm2 per sr.
Immunohistochemistry
Removed specimens were fixed with 10% paraformaldehyde and
embedded in paraffin. Tissue sections (5 mm) deparaffinized in
xylene were passed through graded alcohols before being treated
with 1% H2O2 (v/v) in H2O for 20minutes at room temperature.
After washing the sections three times with PBS, sections were
blocked for 20minutes with 10% FCS diluted in PBS. All incubations
were performed at room temperature in a moist chamber. The slides
were incubated overnight at 41C with anti-acetyl-histone H3 (Lys 18)
antibody (no. 9675, Cell Signaling Technology) diluted 1:100 in
blocking solution. The sections were washed in PBS and incubated
with biotinylated goat anti-rabbit secondary antibody (Vector
Laboratories, Burlingame, CA), and staining was visualized using a
streptavidin–peroxidase conjugate (Vector Laboratories). A diamino-
benzidine substrate kit (Vector Laboratories) was used for color
(brown) visualization, and sections were counterstained with
hematoxylin.
Statistical analysis
P-values based on two-sided Student’s t-test, Mann–Whitney test, or
Kruskal–Wallis test were obtained using the Instat software package
(GraphPad, San Diego, CA). Differences between groups were
considered significant if Po0.05.
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Figure S1. Expression of HLA class I (A, B, C) and Fas (CD95/Apo-1) in human
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Figure S2. Increase of perforin in PHA-stimulated human T cells by exposure
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